目的 研究玻璃体腔注射康柏西普治疗糖尿病视网膜病变患者的疗效及对视觉功能的影响。方法 将我院收治的糖 尿病视网膜病患者110例(110眼)按1:1随机分为观察组和对照组，观察组55例(55只眼)给予玻璃体腔注射康柏西普 治疗，对照组55例(55只眼)给予玻璃体腔注射曲安奈德治疗，比较两组疗效。结果 两组患者治疗后最佳矫正视 力均显著提高(P<0.05)，且观察组提高幅度大于对照组(P<0.05)；两组患者治疗后血清血管内皮生长因子水平均 显著下降(P<0.05)，且观察组下降幅度大于对照组(P<0.05)；对照组总不良反应率为27.27%，显著高于观察组的 5.45%(P<0.05)。结论 玻璃体腔注射康柏西普可有效改善糖尿病视网膜病变患者视觉功能，降低血管内皮生长因子 水平，且安全性较高。

Objective To study the efficacy of intravitreal injection of Conbercept on patients with diabetic retinopathy and its effects on visual function. Methods 110 DR patients (110 eyes) treated in our hospital were randomly divided into the observation group and the control group. The observation group (n=55, 55 eyes) was given intravitreal injection of Conbercept, and the control group (n=55, 55 eyes) was given intravitreal injection of triamcinolone acetonide. The efficacy of the two groups was compared. Results The best corrected visual acuity of the two groups were significantly improved after treatment (P<0.05), and the improvement in the observation group was higher than that in the control group (P<0.05). The level of serum vascular endothelial growth factor in the two groups was decreased significantly after treatment (P<0.05), and the decrease in the observation group was lower than that in the control group (P<0.05). The total adverse reaction rate in the control group was higher than that in the observation group (27.27% vs. 5.45%) (P<0.05). Conclusion Intravitreal injection of Conbercept can not only effectively improve patients’ visual performance, but also significantly reduce the VEGF level in patients with diabetic retinopathy, and it has high safety.